Sesen Bio, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SESN research report →
Price Chart
About the company
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer.
- CEO
- Thomas R. Cannell D.V.M.
- IPO
- 2014
- Employees
- 17
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on SESN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $127.96M
- P/E
- 0.00
- PEG
- 0.00
- P/S
- 0.00
- P/B
- -0.01
- EV/EBITDA
- -0.05
- Div Yield
- 0.00%
- Gross Margin
- 99.21%
- Op Margin
- 84.06%
- Net Margin
- 77.22%
- ROE
- -149.10%
- ROIC
- -36224.76%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $0
- Net Income
- $-60,477,000+0.0%
- EPS
- $-1.46+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.96
- 52W Low
- $0.36
- 50D MA
- $0.60
- 200D MA
- $0.62
- Beta
- 0.83
- RSI (14)
- 58
- Avg Volume
- 1.24M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Sesen Bio said Vicineum remained on track for a potential August 18, 2021 PDUFA, with cash at about $110 million and commercial preparations accelerating ahead of a possible launch.· May 10, 2021
- Company reiterated a clear regulatory path, with U.S. approval still targeted for August 18, 2021 and Europe expected in early 2022.
- Management said FDA feedback now suggests no advisory committee is scheduled, but the agency has not yet decided between accelerated and full approval.
- Cash and cash equivalents were about $110 million at March 31, 2021, and management said that should fund operations through the fourth quarter of 2021.
- The planned U.S. CSO is sized at 35 representatives plus up to 10 reimbursement specialists, with annual cost expected to be roughly $10 million to $15 million.
- Leadership emphasized Vicineum’s differentiated profile, arguing it could improve outcomes, reduce healthcare costs, and fit a supply chain built around Fujifilm, Baxter, Cardinal Health, and future Qilu capacity.
For the first quarter ended March 31, 2021, Sesen Bio reported approximately $110 million in cash and cash equivalents. Management did not provide revenue or EPS figures on this call. They said the cash balance should be sufficient to fund operations through the fourth quarter of 2021. For commercialization, the company expects roughly $10 million to $15 million annually for the contract sales organization, and it kept the ATM shut for April and May, with reactivation no sooner than June. Forward-looking guidance remained centered on potential U.S. approval on August 18, 2021, with Europe potentially following in early 2022.
CEO Thomas Cannell framed Vicineum as a highly differentiated bladder cancer therapy with a strong commercial and regulatory setup. He repeatedly said the company believes it has a clear path forward and is preparing for either accelerated approval or, if the FDA decides, full approval. Cannell was optimistic on launch potential, saying the company has a compelling value proposition and what he described as a significant global commercial opportunity, while also stressing the role of urologists, payers, and patients in adoption.
CFO Monica Forbes said the company ended Q1 with approximately $110 million in cash and cash equivalents, up materially from year-end 2020. She said the company is managing the balance sheet through stage-gated investments focused on regulatory work and launch preparation, and noted the ATM was shut down for April and May to minimize dilution. She also said the planned CSO should cost roughly $10 million to $15 million annually, and reiterated that the current cash balance is expected to fund operations through the fourth quarter of 2021.
Analysts focused on whether Vicineum would be approved via accelerated or full approval, and Cannell said the FDA has not yet ruled, with the decision likely coming around the PDUFA date. He said the company is prepared for a confirmatory trial if accelerated approval is required, and expects to be ready to launch a study in the third quarter if needed. Questions also covered manufacturing inspections and the FDA backlog; management said inspections are underway, they expect them to be completed in time for the late-cycle meeting in mid-July, and they remain confident in Fujifilm’s regulatory track record.
The optimistic case is that Vicineum could receive U.S. approval in August with no advisory committee meeting and then benefit from a well-prepared commercial launch. Management believes the drug has a differentiated safety and efficacy profile, a robust supply chain, and broad potential support from physicians, payers, and patients, all of which could help adoption.
The main risks discussed were regulatory uncertainty over accelerated versus full approval and the possibility that a confirmatory study will be required. Management also acknowledged that FDA site inspections have been delayed by the pandemic, and commercial execution will require significant spending as the sales force ramps. The company’s cash position is solid for now, but the planned launch infrastructure and trial work will increase burn.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.0%
- Shares Outstanding
- 203.49M
- Float Shares
- 187.28M
of shares held by institutions
75 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Trv Gp, LLC | 4.09M | 0 |
| Marshall Wace North America L.P. | 393.22K | ▲ 393.22K |
| Parametric Portfolio Associates LLC | 34.98K | 0 |
| Amalgamated Financial Corp. | 32.77K | ▲ 32.77K |
| Reilly Financial Advisors, LLC | 2.00K | 0 |
| Castle Financial & Retirement Planning Associates, Inc. | 1.17K | ▲ 1.17K |
| Hoover Financial Advisors, Inc. | 512 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 6, 23 | Kelly Steven | other | 600,000 |
| Jun 6, 23 | ZWEIFACH SANFORD S | other | 38,700 |
| Jun 6, 23 | Morris Richard Steven | other | 238,000 |
| Jun 6, 23 | Torok Michael | other | 38,700 |
| Jun 6, 23 | Klichinsky Michael | other | 238,000 |
| Jun 6, 23 | Ugwumba Chidozie | other | 38,700 |
| Jun 6, 23 | Morrison Briggs | other | 38,700 |
| Mar 7, 23 | ModernaTX, Inc. | other | 0 |
| Mar 7, 23 | Kelly Steven | other | 625,797 |
| Mar 7, 23 | Kelly Steven | other | 415,968 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SESN coverage
Recent articles, reports, and earnings notes.
No research on SESN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SESN report →Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
businesswire.com · Mar 2
Sesen Bio Stockholders Approve Merger with Carisma Therapeutics
businesswire.com · Mar 2
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
businesswire.com · Feb 28
Sesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Results
businesswire.com · Feb 28
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
businesswire.com · Feb 21
Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma
businesswire.com · Feb 21
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
businesswire.com · Feb 16
Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting
businesswire.com · Feb 16
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.